English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  The efficacy and safety of drugs can vary between different races or ethnic populations because of differences in the relationship of dose to exposure, pharmacodynamic response or clinical efficacy and safety. In the present  post‐hoc  analysis, we assessed the influence of race on the pharmacokinetics, pharmacodynamics, efficacy and safety of monotherapy with the dipeptidyl peptidase‐4 inhibitor, linagliptin, in patients with type 2 diabetes enrolled in two comparable, previously reported randomized phase  III  trials.    Materials and Methods  Study 1 (with a 12‐week placebo‐controlled phase) recruited Japanese patients only (linagliptin,  n  = 159; placebo,  n  = 80); study 2 (24‐week trial) enrolled Asian (non‐Japanese; linagliptin,  n  = 156; placebo,  n  = 76) and white patients (linagliptin,  n  = 180; placebo,  n  = 90).    Results  Linagliptin trough concentrations were equivalent across study and race groups, and were higher than half‐maximal inhibitory concentration, resulting in dipeptidyl peptidase‐4 inhibition >80% at trough. Linagliptin inhibited plasma dipeptidyl peptidase‐4 activity to a similar degree in study 1 and study 2. Linagliptin reduced fasting plasma glucose concentrations by a similar magnitude across groups, leading to clinically relevant reductions in glycated hemoglobin in all groups. Glycated hemoglobin levels decreased to a slightly greater extent in study 1 (Japanese) and in Asian (non‐Japanese) patients from study 2. Linagliptin had a favorable safety profile in each race group.    Conclusions  Trough exposure, pharmacodynamic response, and efficacy and safety of linagliptin monotherapy were comparable among Japanese, Asian (non‐Japanese) and white patients, confirming that the recommended 5‐mg once‐daily dose of linagliptin is appropriate for use among different race groups.

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes